SCHEMBL10003387

SCHEMBL10003387

CCc1cc2c(nc1NC(=O)c1ccc(F)cc1)c(OC(C)C)c(C(=O)O)n2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ P2RY14 Q15391 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ ACSS2 Q9NR19 1/20 0.37
▸ CPT1A P50416 1/20 0.37
▸ CPT1B Q92523 1/20 0.37
▸ LMNA P02545 3/20 0.37
▸ BRPF1 P55201 2/20 0.36
▸ TMIGD3 P0DMS9 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CRHBP P24387 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ CRHR2 Q13324 1/20 0.36
▸ RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003186 0.92 BRPF1 (0.44) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL10003836 0.91 ADORA2A (0.44) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL10003128 0.83 HTT (0.44) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL10003385 0.83 TMIGD3 (0.38) NPC1RAB9AKMT2AMEN1P2RY14
SCHEMBL10003609 0.82 SMO (0.43) KMT2AMEN1SMN1; SMN2LMNAHTT
SCHEMBL10004423 0.82 RAB9A (0.42) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL10003551 0.82 GRIA2 (0.37) ALDH1A1KDM4ELMNAHPGD
SCHEMBL10003219 0.81 MAPT (0.43) NPC1KMT2AMEN1P2RY14ALDH1A1
SCHEMBL10002854 0.81 P2RX3 (0.41) NPC1RAB9AKMT2AMEN1ALDH1A1
SCHEMBL10003720 0.78 SMO (0.39) NPC1RAB9AKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH NPC1 1300/4885RAB9A 1389/4885KMT2A 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback